Regeneron's three-monthly gMG drug Livsayis cleared by FDA

News
Regeneron's three-monthly gMG drug Livsayis cleared by FDA

Treatment choices for people living with generalised myasthenia gravis (gMG) have been extended in the US once again, with Regeneron joining the crowded market with an RNA-based therapy that only needs to be dosed four times a year.

Livsayis (cemdisiran) has been approved by the FDA for adults with AChR antibody-positive gMG, the most common form of the autoimmune disease, which leads to chronic, fluctuating muscle weakness and fatigue. It is the first siRNA-based therapy for gMG and marks Regeneron's entry into the neurology category.

The drug switches off the production of complement C5, so it addresses a tried-and-tested target for gMG therapies. Earlier this week, AstraZeneca's Alexion unit claimed FDA approval for Klygefa (gefurulimab), becoming the fifth C5 inhibitor indicated as a gMG treatment in the US, and Livsayis will also compete with three drugs targeting FcRn.

In the 190-subject NIMBLE trial, a quarterly subcutaneous injection of Livsayis achieved a statistically significant 2.3-point placebo-adjusted improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at 24 weeks in patients with symptomatic gMG and anti-AChR antibodies. There was a 2.2-point improvement with placebo, with separation occurring within two weeks of the first dose.

Historical clinical data from approved C5 inhibitor therapies have shown a placebo-adjusted treatment difference in MG-ADL total scores ranging from reductions of 1.6 to 2.1 points, giving Livsayis a competitive profile compared to current therapies.

Lead investigator Tuan Vu of the University of South Florida Morsani College of Medicine said that, despite the growing number of approved medicines for gMG, many patients still experience "suboptimal disease control, whether from waning of therapeutic effect, inadequate response, or high treatment burden."

In NIMBLE, Livsayis delivered "rapid, deep disease control, maintained through the end of dosing intervals," and its administration regimen makes it "a compelling treatment option."

Roughly 20% to 50% of patients in real-world settings experience an insufficient response to an initial gMG treatment, with some benefitting from switching between medicines and drug classes.

Details of Livsayis' price and launch date in the US have not yet been disclosed, but analysts at GlobalData have predicted that its infrequent dosing and subcutaneous route of administration could propel it to peak sales of $1.9 billion, assuming it is priced at similar levels to current drugs.

A chunk of that forecast is modelled around combination use of Livsayis with Regeneron's anti-C5 antibody Veopoz (pozelimab), which is approved by the FDA to treat CHAPLE disease, but disappointed in the gMG trial. Regeneron is running late-stage trials of the combination regimen in paroxysmal nocturnal haemoglobinuria (PNH) and geographic atrophy (GA).

Regeneron licenses Livsayis from Alnylam under the terms of a $1 billion alliance agreed in 2019.

"As Regeneron's first approved siRNA therapy, this approval marks a meaningful step forward for our neuroscience pipeline as we relentlessly pursue bold, new approaches to transform care for people living with serious neurological diseases," commented the company's chief scientific officer, George Yancopolous.